Skip to content
Events

Details

Comprehensive Genomic Profiling (CGP) is reshaping precision oncology by using next-generation sequencing (NGS) to assess hundreds of cancer-related genes and biomarkers in a single assay. While CGP offers deeper biological insights and more personalised treatment strategies, its clinical impact hinges on rigorous assay validation and thoughtful implementation.

In this webinar, Dr. Mithua Ghosh from Healthcare Global Enterprises Ltd. (HCG) will share findings from one of India’s first large-scale CGP studies—analysing 1,000 patients and demonstrating CGP’s utility in guiding targeted therapies and immunotherapy decisions. Dr. Ghosh will highlight how real-world evidence supports broader adoption across the region, including integration into Molecular Tumor Boards and routine practice via tissue and liquid biopsies.

We’ll also hear from Dr. Timothy Tay of Singapore General Hospital, who will discuss his team’s experience validating the TSO500 assay, offering practical insights into implementing CGP at scale.

Join us to learn how robust validation, regional data, and collaborative approaches can unlock the full potential of CGP in clinical oncology.

The key things you all learn in this webinar are:

  • Understand the key steps and considerations in validating large NGS panels, including TSO500, for clinical use in anatomical pathology.
  • Explore how molecular diagnostics can be integrated into routine pathology workflows to enhance diagnostic precision and patient care.
  • Gain insights from real-world validation experiences at leading institutions, with practical lessons applicable to regional pathology labs.
Date / Time: 3rd December 2025, Wednesday
08:00 am - 09:00 am (Cape Town)
10:00 am - 11:00 pm (Dubai)
11:30 am - 12:30 pm (Delhi)
02:00 pm - 03:00 pm (Singapore)
03:00 pm - 04:00 pm (Seoul / Tokyo)
04:00 pm - 05:00 pm (Melbourne)

Speakers:

Dr. Timothy Kwang Yong Tay
Senior Consultant, Anatomical Molecular Laboratory (ATOM) (formerly known as Translational Pathology Centre) Histopathology Laboratory,
Department of Anatomical Pathology, Singapore General Hospital

Dr. Timothy Tay is a board-certified anatomical pathologist with specialised expertise in breast, bone and soft tissue, and molecular pathology. He graduated from the Yong Loo Lin School of Medicine at the National University of Singapore and completed his postgraduate residency in anatomical pathology. He holds fellowships from both the Royal College of Pathologists (UK) and the Royal College of Pathologists of Australasia.

Dr. Tay was awarded the prestigious SingHealth Health Manpower Development Plan (HMDP) Fellowship, which enabled him to pursue advanced subspecialty training at leading institutions including Memorial Sloan Kettering Cancer Center in New York and the Institute of Pathology at Heidelberg University Hospital in Germany.

His clinical and research interests focus on integrating molecular diagnostics into routine pathology workflows to improve diagnostic accuracy and patient outcomes.

Dr. Mithua Ghosh
Director of Clinical Diagnostics,
Head of the Department of Molecular and Clinical Genomics
Healthcare Global Enterprises Ltd. (HCG)

Dr. Mithua Ghosh is a seasoned cancer biologist with over 20 years of experience in cancer genomics, molecular pathology, and translational research. She completed her postdoctoral fellowship at Wright State University, USA, focusing on oncogenes in the p53 pathway, and later conducted stem cell research at the Terry Fox Laboratory in Vancouver.

At HCG, Dr. Ghosh has led the development of advanced platforms for cancer genomics, liquid biopsy, and molecular diagnostics, establishing a state-of-the-art lab that supports genomic medicine across a national hospital network. She actively contributes to multidisciplinary tumor boards, ethics committees, and scientific advisory panels, and continues to publish and present her work globally.

 

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
3 Dec. 2025
Location
South APAC
Topic
Cancer research, Oncology, Immuno-oncology research, Clinical research products
Register

Related Events

Nov 4
Illumina Innovation Days
Nov 4, 2025 – Dec 5, 2025
Join us as we discuss new innovative technology offerings from the Illumina product pipeline and introduce our newest system – the MiSeq i100 Series.
View Event
Nov 11
AMP 2025 Annual Meeting and Expo
Nov 11, 2025 – Nov 15, 2025
Visit Illumina booth 719 at AMP to explore streamlined workflows and innovative sequencing solutions.
View Event
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see sapac.illumina.com/company/legal.html.

© 2025 Illumina, Inc. All rights reserved.